Immunome (NASDAQ:IMNM) Director Jean Jacques Bienaime Acquires 10,500 Shares

Immunome, Inc. (NASDAQ:IMNM) Director Jean Jacques Bienaime purchased 10,500 shares of the stock in a transaction dated Friday, June 5th. The shares were bought at an average price of $19.45 per share, for a total transaction of $204,225.00. Following the completion of the acquisition, the director owned 43,415 shares in the company, valued at $844,421.75. This represents a 31.90% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Jean Jacques Bienaime also recently made the following trade(s):

• On Friday, May 15th, Jean Jacques Bienaime purchased 5,000 shares of Immunome stock. The shares were bought at an average price of $20.70 per share, for a total transaction of $103,500.00.
• On Wednesday, March 11th, Jean Jacques Bienaime purchased 1,000 shares of Immunome stock. The shares were bought at an average price of $21.55 per share, for a total transaction of $21,550.00.

Immunome Price Performance

NASDAQ:IMNM traded down $0.22 during trading hours on Tuesday, reaching $18.39. The company’s stock had a trading volume of 1,077,310 shares, compared to its average volume of 1,355,343. The company has a market cap of $2.08 billion, a price-to-earnings ratio of -7.73 and a beta of 2.04. Immunome, Inc. has a one year low of $7.96 and a one year high of $27.65. The business’s 50-day moving average is $21.97 and its 200-day moving average is $21.70.

Immunome (NASDAQ:IMNM) last issued its quarterly earnings data on Tuesday, May 12th. The company reported ($0.48) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.60) by $0.12. On average, sell-side analysts predict that Immunome, Inc. will post -2.06 EPS for the current fiscal year.

Analyst Ratings Changes

A number of brokerages recently issued reports on IMNM. Craig Hallum upped their price objective on shares of Immunome from $33.00 to $36.00 and gave the stock a “buy” rating in a report on Wednesday, March 4th. Leerink Partners decreased their price objective on shares of Immunome from $37.00 to $33.00 and set an “outperform” rating for the company in a report on Friday, May 15th. Truist Financial upped their price objective on shares of Immunome from $36.00 to $37.00 and gave the stock a “buy” rating in a report on Thursday, May 28th. Stephens decreased their price objective on shares of Immunome from $33.00 to $30.00 and set an “overweight” rating for the company in a report on Wednesday, March 4th. Finally, Barclays began coverage on shares of Immunome in a report on Thursday, May 28th. They issued an “overweight” rating and a $36.00 price objective for the company. Twelve research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $33.17.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of IMNM. Assetmark Inc. acquired a new position in Immunome during the 3rd quarter worth $39,000. KBC Group NV acquired a new position in Immunome during the 1st quarter worth $60,000. BNP Paribas Financial Markets lifted its position in Immunome by 81.8% during the 2nd quarter. BNP Paribas Financial Markets now owns 6,464 shares of the company’s stock worth $60,000 after acquiring an additional 2,909 shares during the last quarter. Strs Ohio acquired a new position in Immunome during the 4th quarter worth $64,000. Finally, Tower Research Capital LLC TRC lifted its position in Immunome by 121.2% during the 2nd quarter. Tower Research Capital LLC TRC now owns 6,938 shares of the company’s stock worth $65,000 after acquiring an additional 3,802 shares during the last quarter. Institutional investors and hedge funds own 44.58% of the company’s stock.

Immunome Company Profile

Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome’s approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.

The company’s lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.